NCT01758081View on ClinicalTrials.gov

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

NAActive, not recruitingINTERVENTIONAL
Enrollment

25,874

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
InfectionsHuman Cathelicidin Antimicrobial Peptide (hCAP-18)
Interventions
DIETARY_SUPPLEMENT

vitamin D3

Vitamin D3 (cholecalciferol), 2000 IU per day

DRUG

omega-3 fatty acids (fish oil)

Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

DIETARY_SUPPLEMENT

Vitamin D3 placebo

DIETARY_SUPPLEMENT

fish oil placebo

Trial Locations (1)

02215

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT01758081 - Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection) | Biotech Hunter | Biotech Hunter